脂肪变性
医学
组织学
脂肪肝
磁共振成像
活检
胃肠病学
内科学
纤维化
病理
放射科
疾病
作者
Beom Kyung Kim,Nicole Bernstein,Daniel Q. Huang,Nobuharu Tamaki,Kento Imajo,Masato Yoneda,Nancy Sutter,Jinho Jung,Khang Nguyen,Leyna Nguyen,Tracy Le,Egbert Madamba,Lisa Richards,Mark A. Valasek,Cynthia Behling,Claude B. Sirlin,Atsushi Nakajima,Rohit Loomba
摘要
Summary Background Magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) is an excellent biomarker for the non‐invasive quantification of hepatic steatosis. Aim To examine clinical and histologic factors associated with discordance between steatosis grade determined by histology and MRI‐PDFF in patients with non‐alcoholic fatty liver disease (NAFLD) Methods We included 728 patients with biopsy‐proven NAFLD from UC San Diego ( n = 414) and Yokohama City University ( n = 314) who underwent MRI‐PDFF and liver biopsy. Patients were stratified by steatosis, and matched with MRI‐PDFF cut‐points for each steatosis grade: 0 (MRI‐PDFF < 6.4%), 1 (MRI‐PDFF: 6.4%–17.4%), 2 (MRI‐PDFF: 17.4%–22.1%), 3 (MRI‐PDFF ≥ 22.1%). Primary outcome was major discordance defined as ≥2 steatosis grade difference determined by histology and MRI‐PDFF. Results Mean (±SD) age and BMI were 55.3 (±13.8) years and 29.9 (±4.9) kg/m 2 , respectively. The distributions of histology and MRI‐PDFF‐determined steatosis were 5.5% grade 0 ( n = 40), 44.8% 1 ( n = 326, 44.8%), 33.9% 2 ( n = 247), and 15.8% 3 ( n = 115) vs. 23.5% grade 0 ( n = 171), 49.7% 1 ( n = 362), 12.9% 2 ( n = 94), and 13.9% 3 ( n = 101). Major discordance rate was 6.6% ( n = 48). Most cases with major discordance had greater histology‐determined steatosis grade ( n = 40, 88.3%), higher serum AST and liver stiffness, and greater likelihood of fibrosis ≥2, ballooning ≥1 and lobular inflammation ≥2 (all p < 0.05). Conclusion Histology overestimates steatosis grade compared to MRI‐PDFF. Patients with advanced NASH are likely to be upgraded on steatosis grade by histology. These data have important implications for steatosis estimation and reporting on histology in clinical practice and trials, especially in patients with stage 2 fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI